We bring you the latest news from the healthcare about the health care in the United Kingdom.

dinsdag 3 juli 2018

Prostate Cancer and Prostatic Diseases - Table of Contents alert Volume 21 Issue 2

If you are unable to see the message below, click here to view.
Prostate Cancer and Prostatic Diseases
 
TABLE OF CONTENTS

Volume 21, Issue 2

In this issue
Review Article
Article
Correspondence
Also new
AOP
 

Review Article

Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis

Jurate Noreikaite, Patrick Jones, John Fitzpatrick, Ramachandran Amitharaj, Amelia Pietropaolo et al.

Prostate Cancer and Prostatic Diseases 2018 21 :153 - 160; February 27, 2018; 10.1038/s41391-018-0032-2

 

Abstract | Full Text

Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction

M. Samarinas, M. Gacci, A. de la Taille & S. Gravas

Prostate Cancer and Prostatic Diseases 2018 21 :161 - 167; April 24, 2018; 10.1038/s41391-018-0039-8

 

Abstract | Full Text

Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis

Mohannad A. Awad, Thomas W. Gaither, E. Charles Osterberg, Gregory P. Murphy, Nima Baradaran et al.

Prostate Cancer and Prostatic Diseases 2018 21 :168 - 174; January 02, 2018; 10.1038/s41391-017-0028-3

 

Abstract | Full Text

Which technology to select for primary focal treatment of prostate cancer?—European Section of Urotechnology (ESUT) position statement

Roman Ganzer, Vinodh Kumar Adithyaa Arthanareeswaran, Hashim U. Ahmed, Andrea Cestari, Pascal Rischmann et al.

Prostate Cancer and Prostatic Diseases 2018 21 :175 - 186; May 09, 2018; 10.1038/s41391-018-0042-0

 

Abstract | Full Text

Article

Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance

David E. Guy, Avi Vandersluis, Laurence H. Klotz, Neil Fleshner, Alexander Kiss et al.

Prostate Cancer and Prostatic Diseases 2017 21 :187 - 195; December 14, 2017; 10.1038/s41391-017-0010-0

 

Abstract | Full Text

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer

Emma H. Allott, Elizabeth M. Masko, Alexis R. Freedland, Everardo Macias, Kristine Pelton et al.

Prostate Cancer and Prostatic Diseases 2018 21 :196 - 203; May 23, 2018; 10.1038/s41391-018-0045-x

 

Abstract | Full Text

68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology

I. Berger, C. Annabattula, J. Lewis, D. V. Shetty, J. Kam et al.

Prostate Cancer and Prostatic Diseases 2018 21 :204 - 211; June 01, 2018; 10.1038/s41391-018-0048-7

 

Abstract | Full Text

Phase II prospective randomized trial of weight loss prior to radical prostatectomy

Susanne M Henning, Colette Galet, Kiran Gollapudi, Joshua B. Byrd, Pei Liang et al.

Prostate Cancer and Prostatic Diseases 2017 21 :212 - 220; December 04, 2017; 10.1038/s41391-017-0001-1

 

Abstract | Full Text

Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer

Brian F. Chapin, Jenny N. Nguyen, Mary F. Achim, Neema Navai, Stephen B. Williams et al.

Prostate Cancer and Prostatic Diseases 2017 21 :221 - 227; December 11, 2017; 10.1038/s41391-017-0019-4

 

Abstract | Full Text

Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases

L. M. FitzGerald, S. Zhao, A. Leonardson, M. S. Geybels, S. Kolb et al.

Prostate Cancer and Prostatic Diseases 2018 21 :228 - 237; January 03, 2018; 10.1038/s41391-017-0029-2

 

Abstract | Full Text

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study

Devin N. Patel, Tom Feng, Ross M. Simon, Lauren E. Howard, Adriana C. Vidal et al.

Prostate Cancer and Prostatic Diseases 2018 21 :238 - 244; May 23, 2018; 10.1038/s41391-018-0044-y

 

Abstract | Full Text

The association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: analysis of the National Surgical Quality Improvement Program (NSQIP)

Joseph Brito III, Jorge Pereira, Daniel M. Moreira, Gyan Pareek, Christopher Tucci et al.

Prostate Cancer and Prostatic Diseases 2018 21 :245 - 251; June 01, 2018; 10.1038/s41391-018-0051-z

 

Abstract | Full Text

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study

Juzar Jamnagerwalla, Lauren E. Howard, Emma H. Allott, Adriana C. Vidal, Daniel M. Moreira et al.

Prostate Cancer and Prostatic Diseases 2017 21 :252 - 259; December 27, 2017; 10.1038/s41391-017-0030-9

 

Abstract | Full Text

p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer

Benjamin L. Maughan, Liana B. Guedes, Kenneth Boucher, Gaurav Rajoria, Zach Liu et al.

Prostate Cancer and Prostatic Diseases 2018 21 :260 - 268; January 04, 2018; 10.1038/s41391-017-0027-4

 

Abstract | Full Text

Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial

Alessandro Magli, Eugenia Moretti, Annarita Tullio, Gianluca Giannarini, Fabrizio Tonetto et al.

Prostate Cancer and Prostatic Diseases 2018 21 :269 - 276; March 08, 2018; 10.1038/s41391-018-0034-0

 

Abstract | Full Text

Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study

Wei-Ming Li, Nelly Pasaribu, Su-Shin Lee, Wen-Chan Tsai, Chia-Yang Li et al.

Prostate Cancer and Prostatic Diseases 2018 21 :277 - 286; June 01, 2018; 10.1038/s41391-018-0047-8

 

Abstract | Full Text

Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement

Cosimo De Nunzio, Aldo Brassetti, Flavia Proietti, Marianna Deroma, Francesco Esperto et al.

Prostate Cancer and Prostatic Diseases 2017 21 :287 - 292; December 04, 2017; 10.1038/s41391-017-0003-z

 

Abstract | Full Text

Correspondence

Reply to “Phase II prospective randomized trial of weight loss prior to radical prostatectomy”

W. Demark-Wahnefried, S. Rais-Bahrami, R. A. Desmond, J. B. Gordetsky, M. Azrad et al.

Prostate Cancer and Prostatic Diseases 2018 21 :293 - 294; April 24, 2018; 10.1038/s41391-018-0038-9

 

Abstract | Full Text

Reply to the letter by Demark-Wahnefried et al.

William J. Aronson & Susanne M. Henning

Prostate Cancer and Prostatic Diseases 2018 21 :295 - 295; June 01, 2018; 10.1038/s41391-018-0050-0

 

Abstract | Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Prostate Cancer and Prostatic Diseases.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature